Professors Rummel, Vitolo, Hess and Cotter discuss the important developments in the treatment of NHL presented at ASH 2011, at the Post ASH meeting in Paris. They cover the impact of new NHL data on clinical practice and review updates on new data in the areas of follicular, mantle cell and diffuse large B-cell lymphomas. The panel also reviews the latest data on novel therapies discussed at the meeting and the potential impact on daily clinical practice and discuss personal views on next steps in NHL, such as better prognostic markers and the use of biomarkers and stratification markers. They debate the status of 'watch and wait' and CHOP retuximab, vs CVP retuximab for first line treatment. Also the time between therapies and quality of life balance treating for a non-curable disease.
CVP = cyclophosphamide, vincristine, and prednisolone
CHOP = Cyclophosphamide,Hydroxydaunorubicin, Oncovin, and Prednisolone.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).